Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

A Study to Assess the Effect of QAW039 in Non-atopic Asthmatic Patients

ClinicalTrials.gov ID: NCT01836471

Public ClinicalTrials.gov record NCT01836471. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 10:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Double-blind, Placebo-controlled, Study Examining the Effect of Orally Administered QAW039 (450 mg QD) on FEV1 and ACQ in Non-atopic, Asthmatic Patients With a Baseline, Pre-bronchodilator FEV1 of 40-80% Predicted, Inadequately Controlled With Low Dose ICS Therapy

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of the study was to assess the clinical effect of QAW039 in non-atopic asthmatics taking low dose Inhaled Corticosteroid (ICS) as background therapy.

Study identification

NCT ID
NCT01836471
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Novartis Pharmaceuticals
Industry
Enrollment
345 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 30, 2013
Primary completion
Jan 31, 2016
Completion
Jan 31, 2016
Last update posted
Mar 19, 2017

2013 – 2016

United States locations

U.S. sites
30
U.S. states
15
U.S. cities
27
Facility City State ZIP Site status
Novartis Investigative Site Encinitas California 92024
Novartis Investigative Site Huntington Beach California 92647
Novartis Investigative Site Los Angeles California 90025
Novartis Investigative Site Los Angeles California 90048
Novartis Investigative Site Mission Viejo California 92691
Novartis Investigative Site Orange California 92868
Novartis Investigative Site Palmdale California 93551
Novartis Investigative Site Riverside California 92506
Novartis Investigative Site Rolling Hills Estates California 90274
Novartis Investigative Site San Diego California 92123
Novartis Investigative Site San Jose California 95117
Novartis Investigative Site Stockton California 95207
Novartis Investigative Site Colorado Springs Colorado 80907
Novartis Investigative Site Denver Colorado 80206
Novartis Investigative Site Denver Colorado 80230
Novartis Investigative Site Sarasota Florida 34233
Novartis Investigative Site Owensboro Kentucky 42301
Novartis Investigative Site North Dartmouth Massachusetts 02747
Novartis Investigative Site Minneapolis Minnesota 55402
Novartis Investigative Site St Louis Missouri 63128
Novartis Investigative Site St Louis Missouri 63141
Novartis Investigative Site Papillion Nebraska 68046
Novartis Investigative Site Skillman New Jersey 08558
Novartis Investigative Site Charlotte North Carolina 28207
Novartis Investigative Site Cincinnati Ohio 45231
Novartis Investigative Site Medford Oregon 97504-8741
Novartis Investigative Site Portland Oregon 97213
Novartis Investigative Site Lincoln Rhode Island 02865
Novartis Investigative Site Charleston South Carolina 29407
Novartis Investigative Site Seattle Washington 98104

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 46 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01836471, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 19, 2017 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01836471 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →